Literature DB >> 22990459

Antenatal surveillance of fetal growth restriction.

Jennifer L Thompson1, Jeffrey A Kuller, Eleanor H Rhee.   

Abstract

Fetal growth restriction is a complex problem in modern obstetrics. It is a condition of suboptimal fetal growth based on a genetically predetermined potential and affects approximately 5% to 10% of pregnancies. It is traditionally defined as an estimated fetal weight less than the 10th percentile. Those pregnancies that are affected by growth restriction are associated with increased risk of perinatal morbidity and mortality. Because of this increased risk, these pregnancies are monitored more closely to try to identify those fetuses at the greatest risk of fetal demise and initiate delivery before this critical event. Although the ideal management strategy is still being determined, there are several modalities available to assist in assessment of the growth-restricted fetus. These include the nonstress test test, biophysical profile, and Doppler velocimetry, most commonly of the fetal umbilical artery, in addition to sonographic growth assessment. The use of multiple fetal assessment tools may help improve the prediction of adverse outcomes and initiate delivery before cardiovascular collapse.

Mesh:

Substances:

Year:  2012        PMID: 22990459     DOI: 10.1097/OGX.0b013e31826a5c6f

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  3 in total

1.  Impaired fetoplacental angiogenesis in growth-restricted fetuses with abnormal umbilical artery doppler velocimetry is mediated by aryl hydrocarbon receptor nuclear translocator (ARNT).

Authors:  Emily J Su; Hong Xin; Ping Yin; Matthew Dyson; John Coon; Kathryn N Farrow; Karen K Mestan; Linda M Ernst
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

2.  Overexpression of the aryl hydrocarbon receptor nuclear translocator partially rescues fetoplacental angiogenesis in severe fetal growth restriction.

Authors:  Shuhan Ji; Hong Xin; Emily J Su
Journal:  Clin Sci (Lond)       Date:  2019-06-20       Impact factor: 6.124

3.  Irisin in idiopathic foetal growth restriction.

Authors:  Mete Çağlar; Mehmet Göksu; Bekir Sıtkı Isenlik; Ali Yavuzcan; Musa Yılmaz; Yusuf Üstün; Suleyman Aydin; Selahattin Kumru
Journal:  J Endocrinol Invest       Date:  2014-05-01       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.